The Technological Leap Of Stereotactic Breast Biopsy

https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812

Over the past 30 years since its inception, stereotactic breast biopsy has undergone a leapfrog development, from "blind" to "visual," and from "manual" to "intelligent." Today, this technology stands on the threshold of a new round of transformation.

I. Iteration of Imaging Technology

Early stereotactic systems relied on simulated mammograms, resulting in limited positioning accuracy. Today, digital breast tomography (DBT) has become mainstream. It reconstructs 1mm thick tomographic images by acquiring dozens of low-dose projection images, making overlapping breast fibrous tissue "transparent," improving lesion clarity by more than 40%. Building on this, contrast-enhanced spectral mammography (CESM) further combines with iodine contrast agents, simultaneously displaying morphological and hemodynamic information, providing richer evidence for biopsy.

II. Innovations in Biopsy Needle Design

1. Vacuum-Assisted Biopsy Needle (VAB): Compared to traditional hollow needles, VABs utilize continuous negative pressure to increase the amount of tissue sample obtained in a single procedure by 3–5 times, making them particularly suitable for the complete removal of small calcifications.

2. Adjustable Bending Biopsy Needle: The needle tip angle can be adjusted within the range of 0–90°, solving the problem of limited puncture angles for deep lesions.

3. Visualized Biopsy Needle: The needle tip integrates a miniature ultrasound or optical sensor, displaying the tissue surrounding the needle tip in real time, achieving "eyes in front of the hand."

III. The Rise of Robot-Assisted Systems

Robotic stereotactic biopsy systems have entered the clinical trial stage. Their core advantages are:

- Sub-millimeter precision: Eliminating hand tremors, positioning error <0.5mm;

- Automated process: Automatically completing the entire process of coordinate calculation, needle insertion, and sampling;

- Remote operation: Experts can guide or perform biopsies across geographical locations, addressing the problem of insufficient medical resources at the grassroots level.

IV. Deep Integration of Artificial Intelligence

AI is increasingly being used in stereotactic biopsy:

- Automatic lesion identification: AI algorithms can mark suspicious calcification clusters within seconds, reducing missed diagnoses;

- Puncture path planning: Automatically generating the optimal puncture path by comprehensively considering vascular distribution and glandular density;

- Prognostic prediction: Predicting tumor invasiveness and treatment response based on biopsy tissue images.

V. Fusion of Molecular Diagnostics and Biopsy

Future biopsy needles will not only be sampling tools but also front-end interfaces for molecular diagnostics. By integrating microfluidic chips at the needle tip, the following can be achieved:

- Point-of-care testing (POCT): On-site analysis of estrogen receptor status;

- Liquid biopsy: Simultaneous collection of tissue fluid for circulating tumor DNA detection;

- Drug sensitivity testing: Providing real-time evidence for personalized treatment.

VI. Challenges and Prospects

Despite rapid technological advancements, challenges remain: high costs, radiation dose control, and barriers to multidisciplinary collaboration. However, it is foreseeable that with the deep integration of materials science, robotics, and AI, stereotactic breast biopsy will continue to evolve towards greater precision, safety, and minimal invasiveness, becoming a core pillar for early diagnosis and treatment of breast cancer.